THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN

Objective: Busulfan is a widely used alkylating drug for conditioning of hematopoietic stem cell transplantation (HSCT). Higher exposure of Bu is associated with toxicity and (sinusoidal obstruction syndrome) SOS, whereas lower exposure is associated with graft failure or relapse risk. Therapeutic d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dilek GURLEK GOKCEBAY, ÖzlemArman Bilir, İkbal Ok Bozkaya, Namık Yaşar Özbek, Seda Şahin
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/fa589eab85c64341a65175faae1192f6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa589eab85c64341a65175faae1192f6
record_format	dspace
spelling	oai:doaj.org-article:fa589eab85c64341a65175faae1192f62021-11-10T04:38:53ZTHE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN2531-137910.1016/j.htct.2021.10.1088https://doaj.org/article/fa589eab85c64341a65175faae1192f62021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012359https://doaj.org/toc/2531-1379Objective: Busulfan is a widely used alkylating drug for conditioning of hematopoietic stem cell transplantation (HSCT). Higher exposure of Bu is associated with toxicity and (sinusoidal obstruction syndrome) SOS, whereas lower exposure is associated with graft failure or relapse risk. Therapeutic drug monitoring (TDM) has been recommended to overcome these issues. We aimed in this study to compare HSCT outcomes in children with and without TDM of Bu. Methodology: This retrospective study conducted at our Transplantation Unit between 2012 and 2021. Patients aged 0-18 y underwent HSCT who received Bu-based conditioning and completed post-transplant +100 days included in the study. Data were collected including demographic information, primary diagnoses, conditioning regimen, graft-related data, dose of Bu, time to neutrophil and platelet engraftment, presence of SOS, acute or chronic GvHD, and clinical outcomes. SPSS 18.0 was used for statistical analysis. Results: 172 patients (59 girls, 113 boys) with a median age of 4.70 years (IQR 2.41-10.01) were enrolled in the study. TDM of Bu was performed in 126 patients. 32 patients (19%) developed moderate or severe SOS. Incidence of SOS was significantly higher in the group without TDM. A multivariable analysis showed that presence of acute GVHD and 2 or more alkylating agents in conditioning regimen were associated were SOS. HSCT related outcomes, relapse, OS and EFS did not different between two groups. Conclusion: To improve treatment outcomes of Bu, TDM and dose adjustment, following the first dose, has highly recommended regardless of the dosing guideline was used. We also demonstrated the incidence of SOS decreased in patients with TDM, but other HSCT related outcomes were not influenced. Optimal cumulative Bu exposure canbalance between efficacy and toxicity of HSCT in children.Dilek GURLEK GOKCEBAYÖzlemArman Bilirİkbal Ok BozkayaNamık Yaşar ÖzbekSeda ŞahinElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S62- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Dilek GURLEK GOKCEBAY ÖzlemArman Bilir İkbal Ok Bozkaya Namık Yaşar Özbek Seda Şahin THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN
description	Objective: Busulfan is a widely used alkylating drug for conditioning of hematopoietic stem cell transplantation (HSCT). Higher exposure of Bu is associated with toxicity and (sinusoidal obstruction syndrome) SOS, whereas lower exposure is associated with graft failure or relapse risk. Therapeutic drug monitoring (TDM) has been recommended to overcome these issues. We aimed in this study to compare HSCT outcomes in children with and without TDM of Bu. Methodology: This retrospective study conducted at our Transplantation Unit between 2012 and 2021. Patients aged 0-18 y underwent HSCT who received Bu-based conditioning and completed post-transplant +100 days included in the study. Data were collected including demographic information, primary diagnoses, conditioning regimen, graft-related data, dose of Bu, time to neutrophil and platelet engraftment, presence of SOS, acute or chronic GvHD, and clinical outcomes. SPSS 18.0 was used for statistical analysis. Results: 172 patients (59 girls, 113 boys) with a median age of 4.70 years (IQR 2.41-10.01) were enrolled in the study. TDM of Bu was performed in 126 patients. 32 patients (19%) developed moderate or severe SOS. Incidence of SOS was significantly higher in the group without TDM. A multivariable analysis showed that presence of acute GVHD and 2 or more alkylating agents in conditioning regimen were associated were SOS. HSCT related outcomes, relapse, OS and EFS did not different between two groups. Conclusion: To improve treatment outcomes of Bu, TDM and dose adjustment, following the first dose, has highly recommended regardless of the dosing guideline was used. We also demonstrated the incidence of SOS decreased in patients with TDM, but other HSCT related outcomes were not influenced. Optimal cumulative Bu exposure canbalance between efficacy and toxicity of HSCT in children.
format	article
author	Dilek GURLEK GOKCEBAY ÖzlemArman Bilir İkbal Ok Bozkaya Namık Yaşar Özbek Seda Şahin
author_facet	Dilek GURLEK GOKCEBAY ÖzlemArman Bilir İkbal Ok Bozkaya Namık Yaşar Özbek Seda Şahin
author_sort	Dilek GURLEK GOKCEBAY
title	THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN
title_short	THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN
title_full	THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN
title_fullStr	THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN
title_full_unstemmed	THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN
title_sort	role of therapeutic drug monitoring of intravenous busulfan for prevention of sinusoidal obstruction syndrome in children
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/fa589eab85c64341a65175faae1192f6
work_keys_str_mv	AT dilekgurlekgokcebay theroleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT ozlemarmanbilir theroleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT ikbalokbozkaya theroleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT namıkyasarozbek theroleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT sedasahin theroleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT dilekgurlekgokcebay roleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT ozlemarmanbilir roleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT ikbalokbozkaya roleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT namıkyasarozbek roleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren AT sedasahin roleoftherapeuticdrugmonitoringofintravenousbusulfanforpreventionofsinusoidalobstructionsyndromeinchildren
_version_	1718440615824326656

THE ROLE OF THERAPEUTIC DRUG MONITORING OF INTRAVENOUS BUSULFAN FOR PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN

Ejemplares similares